Pharmacokinetic profile of once-daily cyclobenzaprine extended-release

被引：4

作者：

Darwish, Mona ^{[1
]}

Hellriegel, Edward T. ^{[2
]}

机构：

[1] Cephalon Inc, Clin Pharmacol, Frazer, PA 19355 USA

[2] Cephalon Inc, Drug Safety & Disposit, Frazer, PA 19355 USA

来源：

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2010年 / 6卷 / 11期

关键词：

SINGLE-DOSE PHARMACOKINETICS; SKELETAL-MUSCLE SPASM; 30; MG; OPEN-LABEL; HEALTHY-VOLUNTEERS; 2-PERIOD CROSSOVER; DOUBLE-BLIND; PLACEBO; FOOD; CAPSULES;

D O I：

10.1517/17425255.2010.523419

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Areas covered in this review: Results from CER pharmacokinetic studies conducted through August 2010 are summarized. What the reader will gain: This review provides information on the first four studies assessing the single-dose and steady-state pharmacokinetic profile of CER. Take home message: Once-daily CER 30 mg and three-times-daily CIR 10 mg produced comparable systemic exposures to cyclobenzaprine, but pharmacokinetic profiles were qualitatively different. CER was characterized by a single daily peak in cyclobenzaprine concentration versus three peaks/day for CIR. With once-daily dosing of CER, cyclobenzaprine concentration is sustained over 24 h. CER 30 mg provides approximately twice the exposure as CER 15 mg. Systemic exposure to CER is increased in the presence of food and in elderly subjects. Steady-state is achieved by day 7 of dosing.

引用

页码：1425 / 1436

页数：12

共 24 条

[1] [Anonymous], 2008, DECL HELS ETH PRINC
[2] [Anonymous], 1996, ICH HARMONISED TRIPA
[3] Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: Results of two placebo-controlled trials
Borenstein, DG
Korn, S
[J]. CLINICAL THERAPEUTICS, 2003, 25 (04) : 1056 - 1073
[4] Cyclobenzaprine and back pain - A meta-analysis
Browning, R
Jackson, JL
O'Malley, PG
[J]. ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (13) : 1613 - 1620
[5] *CEPH INC, 2008, AMRIX PACK INS
[6] Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review
Chou, R
Peterson, K
Helfand, M
[J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2004, 28 (02) : 140 - 175
[7] DARWISH M, 2009, PM R S, V1, pS131
[8] Comparison of the Single-Dose Pharmacokinetics of Once-Daily Cyclobenzaprine Extended-Release 30 mg and Cyclobenzaprine Immediate-Release 10 mg Three Times Daily in the Elderly A Randomized, Open-Label, Crossover Study
Darwish, Mona
Xie, Fang
[J]. DRUGS & AGING, 2009, 26 (02) : 95 - 101
[9] A Pharmacokinetic Comparison of Single Doses of Once-Daily Cyclobenzaprine Extended-Release 15 mg and 30 mg: A Randomized, Double-Blind, Two-Period Crossover Study in Healthy Volunteers
Darwish, Mona
Chang, Steven
Hellriegel, Edward T.
[J]. CLINICAL THERAPEUTICS, 2009, 31 (01) : 108 - 114
[10] Single-Dose Pharmacokinetics of Once-Daily Cyclobenzaprine Extended Release 30 mg versus Cyclobenzaprine Immediate Release 10 mg Three Times Daily in Healthy Young Adults A Randomized, Open-Label, Two-Period Crossover, Single-Centre Study
Darwish, Mona
Hellriegel, Edward T.
Xie, Fang
[J]. CLINICAL DRUG INVESTIGATION, 2008, 28 (12) : 793 - 801

← 1 2 3 →